MCID: BRC012
MIFTS: 61

Brucellosis

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Brucellosis

MalaCards integrated aliases for Brucellosis:

Name: Brucellosis 12 74 52 58 54 3 43 15 17 71 32
Mediterranean Fever 12 74
Gibraltar Fever 12 52
Undulant Fever 12 52
Malta Fever 12 52
Bang's Disease 12
Maltese Fever 12
Cyprus Fever 52
Rock Fever 52

Characteristics:

Orphanet epidemiological data:

58
brucellosis
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:11077
ICD9CM 34 023 023.9
MeSH 43 D002006
NCIt 49 C84602
SNOMED-CT 67 75702008
MESH via Orphanet 44 D002006
ICD10 via Orphanet 33 A23.0 A23.1 A23.2 more
UMLS via Orphanet 72 C0006309
Orphanet 58 ORPHA1304
UMLS 71 C0006309

Summaries for Brucellosis

NIH Rare Diseases : 52 Brucellosis is a bacterial infection that spreads from animals to people via unpasteurized dairy products or by exposure to contaminated animal products or infected animals. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs. Brucellosis can cause of range of signs and symptoms, some of which may persist or recur. Initial symptoms may include fever, sweats, malaise, anorexia, headache, fatigue, and/or pain in the muscles, joints, and/or back. Symptoms that may persist or recur include fevers, arthritis , swelling of the testicle and scrotum, swelling of the heart (endocarditis ), neurologic symptoms (in up to 5% of cases), chronic fatigue, depression, and/or swelling of the liver or spleen. People who are in jobs or settings that increase exposure to the bacteria are at increased risk for infection. Antibiotics are used to treat brucellosis. Recovery may take a few weeks to several months, and relapses are common. Death from brucellosis is rare, occurring in no more than 2% of cases.

MalaCards based summary : Brucellosis, also known as mediterranean fever, is related to pancytopenia and proliferative glomerulonephritis, and has symptoms including fatigue, fever and back pain. An important gene associated with Brucellosis is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Antitubercular Agents and Antibiotics, Antitubercular have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A primary bacterial infectious disease that is caused by the bacteria of the genus Brucella, when humans come in contact with contaminated animals or animal products or ingestion of infected food products. The disease has symptom fever, has symptom sweat, has symptom headache, has symptom back pain, has symptom physical weakness, has symptom joint pain and has symptom fatigue.

CDC : 3 Brucellosis is an infectious disease caused by bacteria. People can get the disease when they are in contact with infected animals or animal products contaminated with the bacteria. Animals that are most commonly infected include sheep, cattle, goats, pigs, and dogs, among others.

Wikipedia : 74 Brucellosis is a highly contagious zoonosis caused by ingestion of unpasteurized milk or undercooked... more...

Related Diseases for Brucellosis

Diseases related to Brucellosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1160)
# Related Disease Score Top Affiliating Genes
1 pancytopenia 31.4 IL6 IFNG CRP CD40LG
2 proliferative glomerulonephritis 31.2 IL6 IL4 IFNG
3 encephalitis 31.1 TNF IL6 IL10 CD40LG
4 orchitis 31.0 TNF IL6 IL2 IL10 CRP CD40LG
5 infective endocarditis 31.0 TNF IL6 IL17A CRP
6 syphilis 30.9 IL17A CRP CD40LG
7 polyarteritis nodosa 30.9 MEFV IL6 CRP
8 plague 30.9 TNF TLR4 IL6 IL10 CD86
9 meningoencephalitis 30.9 TNF IL6 IL10 CRP CD40LG
10 disseminated intravascular coagulation 30.9 TNF IL6 IL10 CRP
11 endocarditis 30.9 TNF IL6 IL17A IL10 IFNG CXCL8
12 lupus erythematosus 30.9 TNF IL10 IFNG CD86 CD40LG
13 hidradenitis suppurativa 30.9 TNF TLR4 IL17A IFNG
14 ige responsiveness, atopic 30.8 IL4 IL10 IFNG
15 cryopyrin-associated periodic syndrome 30.8 IL6 IL1RN CRP
16 polyradiculoneuropathy 30.8 IL17A IL10 IFNG CD40LG
17 hidradenitis 30.8 TNF TLR4 IL17A IFNG
18 hypersplenism 30.8 TLR4 IL4 IFNG
19 hyper-igd syndrome 30.8 SAA1 IL1RN CRP
20 coccidioidomycosis 30.7 TLR4 IL17A CD40LG
21 pericardial effusion 30.7 IL6 CRP CD40LG
22 tenosynovitis 30.7 TNF IL6 CRP CD40LG
23 mouth disease 30.7 TLR4 IL6 IL10 IFNG CRP
24 epidemic typhus 30.7 TLR4 CRP CD40LG
25 tularemia 30.7 TNF TLR4 SLC11A1 IL6 IL18 IL17A
26 hereditary periodic fever syndrome 30.6 TNF MEFV
27 q fever 30.6 TNF TLR4 SLC11A1 IL6 IL4 IL10
28 polyarticular juvenile idiopathic arthritis 30.6 TNF IFNG
29 drug reaction with eosinophilia and systemic symptoms 30.6 TNF CRP
30 polyneuropathy 30.6 TNF IL6 CRP CD40LG
31 irritable bowel syndrome 30.6 TNF TLR4 IL6 IL10 CXCL8
32 intestinal tuberculosis 30.6 TNF IFNG CRP
33 tuberculous meningitis 30.6 TNF TGFB1 CXCL8
34 radiculopathy 30.6 IL6 IL17A IL10 CXCL8
35 septic arthritis 30.6 TLR4 IFNG CXCL8 CRP
36 tendinitis 30.6 TNF IL6 CRP
37 dacryoadenitis 30.6 TGFB1 IL17A IL10
38 chronic kidney disease 30.6 TNF TGFB1 IL6 IL10 CRP
39 campylobacteriosis 30.5 TLR4 SLC11A1 IFNG
40 fabry disease 30.5 TNF IL6 CRP
41 typhoid fever 30.5 TNF TLR4 SLC11A1 IL6 IFNG CRP
42 papilledema 30.5 IL1RN CRP CD40LG
43 arthropathy 30.5 TNF IL6 IL1RN IFNG CRP
44 henoch-schoenlein purpura 30.5 MEFV CRP CD40LG
45 crohn's colitis 30.5 TNF IL2 IFNG CXCL8
46 migraine with or without aura 1 30.5 TNF IL6 CRP CD40LG
47 posterior scleritis 30.5 TNF CRP
48 myelitis 30.5 TNF IL6 IL17A IL10 CXCL8 CD40LG
49 neuritis 30.4 TNF IL6 IL4 IL10 IFNG CXCL8
50 histiocytosis 30.4 TNF IL1RN IL17A

Graphical network of the top 20 diseases related to Brucellosis:



Diseases related to Brucellosis

Symptoms & Phenotypes for Brucellosis

Symptoms:

12
  • fatigue
  • fever
  • back pain
  • headache
  • joint pain
  • sweat
  • physical weakness

GenomeRNAi Phenotypes related to Brucellosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 CD40LG CXCL8 IL10 IL17A IL18 IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 CD40LG CXCL8 IL10 IL17A IL18 IL2

MGI Mouse Phenotypes related to Brucellosis:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.4 CD40LG CD86 CRP IFNG IL10 IL17A
2 hematopoietic system MP:0005397 10.39 CD40LG CD86 IFNG IL10 IL17A IL18
3 immune system MP:0005387 10.38 CD40LG CD86 CRP IFNG IL10 IL17A
4 cellular MP:0005384 10.36 CD40LG CD86 IFNG IL10 IL18 IL1RN
5 cardiovascular system MP:0005385 10.3 CD40LG CRP IFNG IL10 IL18 IL1RN
6 digestive/alimentary MP:0005381 10.28 IFNG IL10 IL17A IL18 IL2 IL4
7 mortality/aging MP:0010768 10.25 CD40LG IFNG IL10 IL17A IL18 IL1RN
8 integument MP:0010771 10.23 CD40LG IFNG IL10 IL17A IL18 IL1RN
9 endocrine/exocrine gland MP:0005379 10.22 CD40LG CD86 IFNG IL10 IL17A IL2
10 liver/biliary system MP:0005370 10.09 IFNG IL10 IL2 IL4 IL6 MEFV
11 reproductive system MP:0005389 10 CD40LG IFNG IL10 IL1RN IL2 IL4
12 muscle MP:0005369 9.97 CD86 IFNG IL10 IL18 IL6 TGFB1
13 neoplasm MP:0002006 9.92 IFNG IL10 IL2 IL6 SLC11A1 TGFB1
14 respiratory system MP:0005388 9.81 IFNG IL10 IL17A IL2 IL4 IL6
15 skeleton MP:0005390 9.7 CD40LG IFNG IL10 IL17A IL1RN IL4
16 vision/eye MP:0005391 9.28 IFNG IL10 IL18 IL2 IL4 IL6

Drugs & Therapeutics for Brucellosis

Drugs for Brucellosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antitubercular Agents Phase 4
2 Antibiotics, Antitubercular Phase 4
3 Anti-Bacterial Agents Phase 4
4 Anti-Infective Agents Phase 4
5
Colchicine Approved Phase 3 64-86-8 6167 2833
6 Interleukin 1 Receptor Antagonist Protein Phase 3
7 Pharmaceutical Solutions Phase 3
8 Antimitotic Agents Phase 3
9 Antirheumatic Agents Phase 3
10 Immunoglobulin A Phase 3
11
Rilonacept Approved, Investigational Phase 2 501081-76-1 104924
12 Anti-Inflammatory Agents Phase 2
13 Antibodies, Monoclonal Phase 1, Phase 2
14 Immunologic Factors Phase 1, Phase 2
15 Antibodies Phase 1, Phase 2
16 Immunoglobulins Phase 1, Phase 2
17
Norgestimate Approved, Investigational Phase 1 35189-28-7 6540478
18
Isoniazid Approved, Investigational Phase 1 54-85-3 3767
19
Moxifloxacin Approved, Investigational Phase 1 151096-09-2, 354812-41-2 152946
20
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
21
Rifampicin Approved Phase 1 13292-46-1 5458213 5381226
22
Kanamycin Approved, Investigational, Vet_approved Phase 1 59-01-8, 8063-07-8 6032
23
Polyestradiol phosphate Approved Phase 1 28014-46-2
24
Estradiol Approved, Investigational, Vet_approved Phase 1 50-28-2 5757
25
Ethinyl Estradiol Approved Phase 1 57-63-6 5991
26
Pyrazinamide Approved, Investigational Phase 1 98-96-4 1046
27
Streptomycin Approved, Vet_approved Phase 1 57-92-1 19649
28
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
29 Catalase Phase 1
30 Vitamin B3 Phase 1
31 Hypolipidemic Agents Phase 1
32 Norgestimate, ethinyl estradiol drug combination Phase 1
33 Contraceptive Agents Phase 1
34 Cytochrome P-450 CYP3A Inducers Phase 1
35 Estradiol 17 beta-cypionate Phase 1
36 Topoisomerase Inhibitors Phase 1
37 Contraceptives, Oral, Combined Phase 1
38 Contraceptives, Oral Phase 1
39 Fluoroquinolones Phase 1
40 Nicotinic Acids Phase 1
41 Antimetabolites Phase 1
42 Lipid Regulating Agents Phase 1
43 Estradiol 3-benzoate Phase 1
44 Immunoglobulin G
45 Immunoglobulin M

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial Completed NCT02602028 Phase 4 colchicine
2 Comparison of Two Antimicrobial Therapy Duration (6 Weeks Versus 12 Weeks)for Spondylodiscitis Completed NCT00764114 Phase 4 antibiotic
3 A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Completed NCT01705756 Phase 3 Kineret
4 An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF)) Completed NCT02911857 Phase 3
5 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
6 A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs Completed NCT02059291 Phase 3 Canakinumab;Placebo
7 A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis Completed NCT00035334 Phase 2, Phase 3 NC-503 (Anti-amyloidotic (AA) Agent)
8 Colchicine Cardiovascular Outcomes Trial (COLCOT) Completed NCT02551094 Phase 3 colchicine;colchicine placebo
9 Colchicine in Postoperative Fontan Patients (CPFP) Recruiting NCT03575572 Phase 2, Phase 3 Colchicine
10 Evaluation of Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Not yet recruiting NCT04008316 Phase 3 Colchicine
11 Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation Unknown status NCT02175589 Phase 2
12 The Effect of Colchicine Treatment on the Progression of Proteinuria in Patients With Diabetic Nephropathy. Unknown status NCT02442921 Phase 1, Phase 2 Colchicine;Placebo
13 An Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever Completed NCT01088880 Phase 2 Canakinumab
14 A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever Completed NCT01148797 Phase 2 Canakinumab
15 Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF) Completed NCT00582907 Phase 2 Rilonacept;Placebo
16 Continuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study Pathogenesis Completed NCT00094900 Phase 2 IL-1 Trap
17 Ilaris (Canakinumab) in the Schnitzler Syndrome. A Case Series. Completed NCT01245127 Phase 2 Ilaris
18 Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study Recruiting NCT03446209 Phase 2 Tocilizumab Infusion RoAcemtra (EU);0.9% physiological saline
19 A Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) Assessing Safety and Biomarker Changes in Boys With Duchenne Muscular Dystrophy Recruiting NCT03936894 Phase 1, Phase 2 Canakinumab Injection [Ilaris]
20 Effects of Probiotic Addition to Corticosteroid Treatment for PFAPA Withdrawn NCT02535962 Phase 2
21 An Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMF Completed NCT01075906 Phase 1 colchicine sprinkle capsules;colchicine sprinkle capsules
22 Pharmacokinetics of Standard First and Second Line Anti-TB Drugs in the Lung and Lesions of Subjects Elected for Resection Surgery Completed NCT00816426 Phase 1 Rifampicin;Isoniazid;Pyrazinamide;Kanamycin;Moxifloxacin
23 Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA) Recruiting NCT02775994 Phase 1 Canakinumab
24 Application of Dynamic Contrast Enhanced MRI in Clinical and Early Diagnosis of Brucellar Spondylitis Unknown status NCT02809625
25 Exertional Muscle Fatigue In FMF Patients Evaluated By MRI And MR Spectroscopy Of The Thigh Unknown status NCT00658060
26 Association Between Basal Proteinuria Levels and Pregnancy Outcomes in Familial Mediterranean Fever Unknown status NCT02092064
27 Life Quality Study for PFAPA Patient Unknown status NCT02811705
28 Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level Unknown status NCT01168570
29 Gluten-related Disorders in Patients Affected With Familial Mediterranean Fever Completed NCT03563300
30 Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan Completed NCT01766830
31 Genetics and Pathophysiology of Autoinflammatory Disorders. Recruiting NCT00001373
32 Real World Study of Classic Infectious Disease Recruiting NCT04020536 Antibiotics
33 Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases Recruiting NCT02466217
34 Creation of a Tool to Assess Quality of Life in Patient With Auto-inflammatory Diseases Active, not recruiting NCT03569644
35 Heat Intolerance in the Group of FMF Patients Enrolling by invitation NCT01059279
36 Assessment of a Functional Test to Detect Familial Mediterranean Fever Not yet recruiting NCT03747315
37 Musculoskeletal Ultrasound of the Ankles in Erysipelas-like Erythema of Familial Mediterranean Fever Not yet recruiting NCT03917277
38 Immunome Project Consortium for Autoinflammatory Disorders Not yet recruiting NCT03919110
39 Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency Terminated NCT00260299
40 The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever. Withdrawn NCT02021084
41 Inflammatory Proteins in Familial Mediterranean Fever During Attack and Remission Withdrawn NCT00323440

Search NIH Clinical Center for Brucellosis

Cochrane evidence based reviews: brucellosis

Genetic Tests for Brucellosis

Anatomical Context for Brucellosis

MalaCards organs/tissues related to Brucellosis:

40
Testes, Liver, Heart, Bone, T Cells, Skin, Spleen

Publications for Brucellosis

Articles related to Brucellosis:

(show top 50) (show all 10039)
# Title Authors PMID Year
1
Cloning, expression and characterization of immunogenic aminopeptidase N from Brucella melitensis. 54 61
17064279 2006
2
Limited diagnostic usefulness of antibodies to cytoplasmic proteins of Brucella in early-treated human brucellosis. 54 61
11303810 2001
3
The 18-kDa cytoplasmic protein of Brucella species --an antigen useful for diagnosis--is a lumazine synthase. 54 61
10482294 1999
4
Serological follow-up of human brucellosis by measuring IgG antibodies to lipopolysaccharide and cytoplasmic proteins of Brucella species. 54 61
8852961 1996
5
Seroprevalence of human brucellosis and molecular characteristics of Brucella strains in Inner Mongolia Autonomous region of China, from 2012 to 2016. 61
31997725 2020
6
Association between polymorphisms of cytokine genes and brucellosis: A comprehensive systematic review and meta-analysis. 61
31816580 2020
7
Brucellar epididymo-orchitis: a retrospective study of 25 cases. 61
30767606 2020
8
Relationship of meteorological factors and human brucellosis in Hebei province, China. 61
31740063 2020
9
A primary investigation of the relation between the incidence of brucellosis and climatic factors in Iran. 61
31712119 2020
10
Zoonotic disease awareness survey of backyard poultry and swine owners in southcentral Pennsylvania. 61
32020787 2020
11
Brucellosis: A rapid risk assessment by a regional outbreak team and its coordinated response with the Directorate-General for Food and Veterinary, North region of Portugal, 2019. 61
32034877 2020
12
Mannosylated chitosan nanoparticles loaded with FliC antigen as a novel vaccine candidate against Brucella melitensis and Brucella abortus infection. 61
32017955 2020
13
Dendritic cells and Brucella spp. interaction: the sentinel host and the stealthy pathogen. 61
30783994 2020
14
Brucellosis associated with stillbirth in a bottlenose dolphin in Australia. 61
32030727 2020
15
Deletion of the LuxR-type regulator VjbR in Brucella canis affects expression of type IV secretion system and bacterial virulence, and the mutant strain confers protection against Brucella canis challenge in mice. 61
31715318 2020
16
Contamination of milk and dairy products by Brucella species: A global systematic review and meta-analysis. 61
31955745 2020
17
The prevalence of Brucella spp. in dairy products in the Middle East region: A systematic review and meta-analysis. 61
31669529 2020
18
Diagnosis of canine brucellosis: comparison of various serologic tests and PCR. 61
31752635 2020
19
Brucellosis in India: results of a collaborative workshop to define One Health priorities. 61
31620958 2020
20
Evaluation of serological diagnostic tests of human brucellosis for prevention and control in Mexico. 61
31960174 2020
21
Zagros Mountains: A region in Iran with extremely high incidence of Brucellosis. 61
31971123 2020
22
Interaction of Brucella abortus with osteoclasts: a step towards understanding osteoarticular brucellosis and vaccine safety. 61
31932325 2020
23
ELISA is superior to bacterial culture and agglutination test in the diagnosis of brucellosis in an endemic area in China. 61
31906870 2020
24
Comparative evaluation of fluorescence polarization assay and competitive ELISA for the diagnosis of bovine brucellosis vis-a-vis sero-monitoring. 61
32014437 2020
25
Chronic brucellosis with hepatic brucelloma and AA amyloidosis in a patient with autosomal dominant polycystic kidney disease. 61
32039060 2020
26
Neurobrucellosis: A neglected entity? An update from tertiary care Neurocentre of South East Asia. 61
32001377 2020
27
Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection. 61
31951645 2020
28
An optimized five-color/seven-parameter flow cytometry panel for immunophenotyping guinea pig peripheral blood lymphocytes. 61
31682796 2020
29
Zoonotic Diseases in Oman: Successes, Challenges, and Future Directions. 61
31486732 2020
30
A man with recurrent fever, arthritis, and rashes-brucellosis? A case report. 61
31910802 2020
31
Serological Evidence of Yersiniosis, Tick-Borne Encephalitis, West Nile, Hepatitis E, Crimean-Congo Hemorrhagic Fever, Lyme Borreliosis, and Brucellosis in Febrile Patients Presenting at Diverse Hospitals in Kenya. 61
31928511 2020
32
High index of suspicion for brucellosis in a highly cosmopolitan city in southern China. 61
31914937 2020
33
Sero-prevalence and risk factors of brucellosis among suspected febrile patients attending a referral hospital in southern Saudi Arabia (2014-2018). 61
31918671 2020
34
Spatial-temporal distribution of human brucellosis in mainland China from 2004 to 2017 and an analysis of social and environmental factors. 61
31898483 2020
35
Epidemiological features of human brucellosis in Tongliao City, Inner Mongolia province, China: a cross-sectional study over an 11-year period (2007-2017). 61
31900267 2020
36
Production of Brucella melitensis Omp16 protein fused to the human interleukin 2 in Lactococcus lactis MG1363 toward developing a Lactococcus-based vaccine against brucellosis. 61
31574230 2020
37
Brucella abortus S19 rfbD mutant is highly attenuated, DIVA enable and confers protection against virulent challenge in mice. 61
31843357 2020
38
Transcriptomic analysis of smooth versus rough Brucella melitensis Rev.1 vaccine strains reveals insights into virulence attenuation. 61
31699441 2020
39
Brucella melitensis omp31 mutant is attenuated and confers protection against virulent Brucella melitensis challenge in BALB/c mice. 61
31986561 2020
40
Susceptibility of Avian Species to Brucella Infection: A Hypothesis-Driven Study. 61
31991609 2020
41
Brucella Exposure Risk Events in 10 Clinical Laboratories, New York City, USA, 2015 to 2017. 61
31694974 2020
42
Risk factors for focal involvement in brucellosis. 61
32037038 2020
43
Brucellosis mimicking herpes simplex virus encephalitis. 61
31876485 2020
44
A case of brucellosis concomitant with HIV infection in China. 61
31948465 2020
45
The Management of Cow Shelters (Gaushalas) in India, Including the Attitudes of Shelter Managers to Cow Welfare. 61
32012807 2020
46
Zoonotic Disease Exposure Risk and Rabies Vaccination Among Wildlife Professionals. 61
31993824 2020
47
Induction of systemic immunity through nasal-associated lymphoid tissue (NALT) of mice intranasally immunized with Brucella abortus malate dehydrogenase-loaded chitosan nanoparticles. 61
32027689 2020
48
Elicitation of Th1/Th2 related responses in mice by chitosan nanoparticles loaded with Brucella abortus malate dehydrogenase, outer membrane proteins 10 and 19. 61
31676233 2020
49
Erratum to: An Outbreak of Brucellosis: An Adult and Pediatric Case Series. 61
31879675 2019
50
Brucellosis as a rare cause of olecranon bursitis: case-based review. 61
31388750 2019

Variations for Brucellosis

Expression for Brucellosis

Search GEO for disease gene expression data for Brucellosis.

Pathways for Brucellosis

Pathways related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.11 TNF TLR4 TGFB1 SLC11A1 SAA1 MEFV
2
Show member pathways
13.91 TNF TGFB1 IL6 IL4 IL2 IL18
3
Show member pathways
13.81 TNF TLR4 TGFB1 IL6 IL4 IL2
4
Show member pathways
13.67 TNF TGFB1 IL6 IL4 IL2 IL18
5
Show member pathways
13.56 TNF TLR4 TGFB1 IL6 IL4 IL2
6
Show member pathways
13.45 TNF TGFB1 IL6 IL4 IL2 IL18
7
Show member pathways
13.41 TNF TGFB1 SAA1 IL6 IL4 IL2
8
Show member pathways
13.28 TNF TLR4 TGFB1 IL6 IL2 IL18
9
Show member pathways
12.99 TNF TGFB1 IL6 IL4 IL2 IL17A
10
Show member pathways
12.97 TNF TLR4 IL6 IL2 IL18 IFNG
11 12.95 TGFB1 IL6 IL4 IL2 IFNG CXCL8
12
Show member pathways
12.92 TNF TLR4 SAA1 IL6 IL18 IFNG
13
Show member pathways
12.83 TNF TLR4 TGFB1 IL6 IL2 CD40LG
14
Show member pathways
12.81 TNF IL4 IL2 IL18 IL10 IFNG
15
Show member pathways
12.78 TNF TLR4 TGFB1 IL6 IL4 IL2
16
Show member pathways
12.77 TNF IL6 IL2 IL18 IL17A IL10
17 12.74 TNF IL4 IL2 IL1RN IL17A IL10
18
Show member pathways
12.71 TNF TLR4 TGFB1 IL6 IL4 IL2
19
Show member pathways
12.52 TNF IL6 IL4 IL17A IFNG CXCL8
20
Show member pathways
12.52 TNF IL6 IL2 IL18 IL10 CXCL8
21
Show member pathways
12.52 TNF SAA1 IL6 IL4 IL2 IFNG
22
Show member pathways
12.49 IL6 IL4 IL2 IL10 IFNG
23
Show member pathways
12.45 TNF TLR4 TGFB1 IL4 IL10 IFNG
24 12.44 TNF TLR4 IL18 CXCL8
25 12.44 TNF TLR4 IL6 IL18 CXCL8
26
Show member pathways
12.43 TNF TLR4 IL6 IFNG CXCL8
27
Show member pathways
12.43 TNF TGFB1 IL6 IL4 IL2 IL18
28 12.42 TNF TLR4 MEFV IL6 IL18 CXCL8
29 12.42 TNF TLR4 TGFB1 IL6 IL18 IL10
30 12.4 TNF TGFB1 IL6 IL2
31
Show member pathways
12.37 TNF IL6 IL1RN IL18 CXCL8
32
Show member pathways
12.37 TNF TLR4 IL6 IL4 IFNG CXCL8
33
Show member pathways
12.34 TNF TLR4 IL6 CXCL8
34 12.34 TNF TLR4 TGFB1 IL6 IFNG
35 12.33 TNF IL6 IL1RN IL10 CXCL8
36
Show member pathways
12.29 TNF IL6 IL2 IL10
37
Show member pathways
12.21 TNF TLR4 IL6 IL4 IFNG
38 12.19 TNF IL6 IL4 IL2 IL10 IFNG
39 12.18 TNF TLR4 MEFV IL6 IL2 IL18
40 12.16 TNF TLR4 TGFB1 IL6 IL4 IL2
41 12.13 TNF TLR4 TGFB1 IL6 IL10 IFNG
42
Show member pathways
12.1 IL4 IL2 IL18 IFNG
43 12.08 TNF TGFB1 SAA1 IL6 IL4 IL18
44
Show member pathways
12.07 TLR4 TGFB1 IL6 IL17A CXCL8
45 12.07 TLR4 TGFB1 IL2 IL18 CXCL8
46 12.06 TGFB1 IL6 IFNG CXCL8
47 12.05 TNF TLR4 CXCL8 CD40LG
48 12.04 TNF TGFB1 IL6 CXCL8
49 12 IL6 IL4 IL2 IFNG CXCL8
50 12 TNF IL4 IL2 IL18 IL17A IL10

GO Terms for Brucellosis

Cellular components related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF TGFB1 SAA1 IL6 IL4 IL2
2 external side of plasma membrane GO:0009897 9.55 TNF TLR4 IL17A CD86 CD40LG
3 extracellular space GO:0005615 9.47 TNF TGFB1 SAA1 IL6 IL4 IL2

Biological processes related to Brucellosis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 TLR4 TGFB1 IL6 IL4 IL1RN IL18
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TNF TLR4 TGFB1 SLC11A1 IL6 IL4
3 positive regulation of transcription, DNA-templated GO:0045893 10.17 TNF TGFB1 IL6 IL4 IL10 CD86
4 positive regulation of protein phosphorylation GO:0001934 10.02 TNF TGFB1 IL2 IFNG
5 positive regulation of protein kinase B signaling GO:0051897 10.01 TNF TGFB1 IL18 CD86
6 positive regulation of gene expression GO:0010628 9.97 TNF TLR4 TGFB1 SLC11A1 IL6 IL4
7 negative regulation of inflammatory response GO:0050728 9.96 SAA1 MEFV IL2 IL10
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.95 TNF TLR4 TGFB1 IL6 IL18 CD40LG
9 cytokine-mediated signaling pathway GO:0019221 9.93 TNF TGFB1 SAA1 IL6 IL4 IL2
10 B cell differentiation GO:0030183 9.91 IL4 IL10 CD40LG
11 cellular response to organic cyclic compound GO:0071407 9.91 TNF TGFB1 IL18
12 positive regulation of inflammatory response GO:0050729 9.91 TNF TLR4 IL2 IL18
13 cellular response to lipopolysaccharide GO:0071222 9.91 TNF TLR4 IL6 IL1RN IL10 CXCL8
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF TLR4 IL18
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF IL6 IL18
16 humoral immune response GO:0006959 9.9 TNF IL6 IFNG
17 negative regulation of fat cell differentiation GO:0045599 9.89 TNF TGFB1 IL6
18 response to glucocorticoid GO:0051384 9.88 TNF IL6 IL1RN IL10
19 positive regulation of phagocytosis GO:0050766 9.87 TNF SLC11A1 IFNG
20 extrinsic apoptotic signaling pathway GO:0097191 9.87 TNF TGFB1 IFNG
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF TLR4 IFNG
22 negative regulation of T cell proliferation GO:0042130 9.86 TGFB1 IL10 CD86
23 positive regulation of interleukin-6 production GO:0032755 9.86 TNF TLR4 IL6 IL1RN
24 positive regulation of B cell proliferation GO:0030890 9.85 TLR4 IL4 IL2
25 positive regulation of protein complex assembly GO:0031334 9.85 TNF TGFB1 IFNG
26 negative regulation of mitotic cell cycle GO:0045930 9.85 TNF TGFB1 IL10
27 acute-phase response GO:0006953 9.85 SAA1 IL6 CRP
28 positive regulation of T cell proliferation GO:0042102 9.85 IL6 IL4 IL2 CD86 CD40LG
29 negative regulation of interleukin-6 production GO:0032715 9.84 TNF TLR4 IL10
30 positive regulation of interleukin-6 secretion GO:2000778 9.83 TNF TLR4 IL17A
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TLR4 TGFB1 IL18
32 positive regulation of interferon-gamma production GO:0032729 9.83 TNF TLR4 SLC11A1 IL2 IL18
33 positive regulation of JAK-STAT cascade GO:0046427 9.82 TNF IL6 IL10
34 positive regulation of cytokine secretion GO:0050715 9.82 TNF SAA1 IL10
35 positive regulation of interleukin-12 production GO:0032735 9.81 TLR4 IFNG CD40LG
36 negative regulation of myoblast differentiation GO:0045662 9.8 TNF TGFB1 IL18
37 positive regulation of osteoclast differentiation GO:0045672 9.79 TNF IL17A IFNG
38 positive regulation of chemokine production GO:0032722 9.77 TNF TLR4 IL6
39 regulation of regulatory T cell differentiation GO:0045589 9.77 TGFB1 IL2 IFNG
40 inflammatory response GO:0006954 9.77 TNF TLR4 TGFB1 SLC11A1 MEFV IL6
41 positive regulation of interleukin-17 production GO:0032740 9.75 TGFB1 IL2 IL18
42 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
43 positive regulation of isotype switching to IgG isotypes GO:0048304 9.74 IL4 IL2
44 negative regulation of interleukin-17 production GO:0032700 9.74 TLR4 TGFB1 IFNG
45 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.73 IL4 IL10
46 T-helper 1 type immune response GO:0042088 9.73 TLR4 IL18
47 endothelial cell apoptotic process GO:0072577 9.73 TNF IL10
48 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF IL6 IL4 IL2 IL18 IFNG
49 positive regulation of T-helper 2 cell differentiation GO:0045630 9.72 IL18 CD86
50 positive regulation of tissue remodeling GO:0034105 9.72 IL2 IL18

Molecular functions related to Brucellosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.4 TNF TGFB1 IL6 IL4 IL2 IL1RN
2 growth factor activity GO:0008083 9.35 TGFB1 IL6 IL4 IL2 IL10

Sources for Brucellosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....